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Background: Patients with psychosis frequently report difficulties getting or staying asleep (insomnia).
Dissatisfaction with sleep is high. Insomnia should be treated in this group, but typically it is not even assessed.
Importantly, recent evidence indicates that insomnia triggers and exacerbates delusions and hallucinations. The
clinical implication is that if the insomnia is treated then the psychotic symptoms will significantly lessen. In a case
series with 15 patients with persecutory delusions resistant to previous treatment this is exactly what we found:
cognitive behavioural therapy for insomnia (CBT-I) led to large reductions in both the insomnia and delusions. The
clear next step is a pilot randomized controlled test. The clinical aim is to test whether CBT-I can reduce both
insomnia and psychotic symptoms. The trial will inform decisions for a definitive large-scale evaluation.
Methods/design: We will carry out a randomized controlled trial (the Better Sleep Trial, or the BEST study) with 60
patients with distressing delusions or hallucinations in the context of a schizophrenia spectrum diagnosis. Half of
the participants will be randomized to receive CBT-I, in addition to their standard treatment, for up to eight
sessions over 12 weeks. The other half will continue with treatment as usual. Blind assessments will take place at 0
weeks, 12 weeks (post-treatment) and 24 weeks (follow-up). The primary outcome hypotheses are that CBT-I added
to treatment as usual will improve sleep, delusions and hallucinations compared with only treatment as usual. All
main analyses will be carried out at the end of the last follow-up assessments and will be based on the intention-to
-treat principle. The trial is funded by the NHS National Institute for Health Research (NIHR) Research for Patient
Benefit Programme. Data collection will be complete by the end of 2014.
Discussion: This will be the first controlled test of CBT-I for patients with delusions and hallucinations. It will
provide significant evidence for an easily administered intervention that is likely to prove very popular with patients
experiencing the difficult-to-treat problems of delusions and hallucinations.
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Improvements in the treatment of delusions and halluci-
nations are greatly needed. One method for improving
treatment involves drawing on developments in under-
standing these psychotic symptoms by targeting key pu-
tative causal factors one at a time (for example, [1-4]).
Insomnia has been strongly implicated in the occurrence
of psychotic symptoms but is yet to be a treatment tar-
get. Harvey et al. [5] explain: ‘Sleep disturbance is in-
creasingly recognized as an important, but understudied,
mechanism in the complex and multifactorial causation
of the symptoms and functional disability associated
with psychiatric disorders.’ Four recent studies by our
group have established in cross-sectional and longitu-
dinal designs that insomnia and paranoid delusions are
linked [6-9]. For instance, in our initial study we found
in a group of patients with persecutory delusions that
27% had severe clinical insomnia, 27% had clinical in-
somnia of moderate severity and 30% had subthreshold
insomnia, that is, only 16% of patients were sleeping
well. While it has long been known that sleep deprivation
can bring on hallucinations [10] and that difficulties
sleeping are one of the most common prodromal signs of
psychotic disorders [11]. Moreover, Yang and Winkleman
[12] have argued that their ‘data demonstrate that drug-
free patients with chronic undifferentiated type schizo-
phrenia suffer from profound disturbances in sleep
continuity and sleep architecture.’ At a neurobiological
level it has been suggested that the overactivity of dopa-
mine D2 receptors in the striatum thought to underlie the
positive symptoms of schizophrenia also enhances wakeful-
ness [13]. The implication is that treating insomnia in pa-
tients with schizophrenia will lessen psychotic symptoms.
Preliminary study
A large body of research, outside of psychosis groups,
has found that cognitive behavioural interventions
(CBT-I) are highly effective in treating insomnia [14,15].
In a recent case series, we used CBT-I with patients with
psychosis for the first time [16]. Fifteen patients with
persistent persecutory delusions and insomnia in the
context of a psychotic disorder were individually given a
standard-format, four-session CBT-I intervention. Out-
come assessments were conducted at pre-treatment,
post-treatment and one-month follow-up. Following the
intervention, highly statistically significant reductions
were found in levels of insomnia and the persecutory de-
lusions. The effect sizes were large, and the changes
were maintained at the time of the follow-up assess-
ment. Nine patients reduced insomnia scores by at least
50% and 14 patients reduced insomnia scores by at least
25%. Five patients reduced persecutory thinking scores
by at least 50% and eight patients reduced persecutory
thinking by at least 25%. There were also significantreductions in levels of hallucinations, anxiety and de-
pression. A more rigorous evaluation is required, which
will test our trial procedures, and include an examin-
ation of the effects of the intervention on delusions and
hallucinations.
Pilot randomized controlled trial
A randomized controlled trial of CBT-I for patients
with psychosis is now warranted. This pilot trial will:
establish recruitment and follow-up rates; indicate
levels of compliance with the treatment; determine
whether actigraphy and sleep diaries can be used in this
population; provide stronger evidence for the efficacy
of the intervention (establishing treatment effect sizes);
and indicate for whom the intervention is most suit-
able. It will test our procedures within a large mental-
health unit in an NHS Trust hospital for recruitment
from inpatient and outpatient services from different
catchment areas. Therefore, there are three specific
main aims: to establish that the trial procedures work
(and fine tune where necessary), so that a Phase III trial
can follow; to show that CBT-I is beneficial in improv-
ing sleep for individuals with distressing delusions or
hallucinations; and to show that CBT-I has the added
benefit of reducing delusions and hallucinations. The
latter aims will establish treatment effect sizes. The pri-
mary outcome hypotheses are:
1. CBT-I added to treatment as usual will improve
sleep in patients with psychosis compared with only
treatment as usual.
2. CBT-I added to treatment as usual will reduce
delusions and hallucinations compared with only
treatment as usual.
The secondary hypotheses are:
1. Improvements in sleep and psychotic symptoms will
be maintained over at least three months.
2. Improvement in sleep will be associated with
improvements in psychotic symptoms.
3. CBT-I will lead to improvements in patient well-
being and feelings of fatigue.
4. There will be indications that CBT-I is potentially
cost-effective, by improving quality of life, reducing




This is a prospective randomized pilot study to evaluate
CBT-I in addition to standard psychiatric care versus
standard psychiatric care alone in patients with
distressing delusions or hallucinations (see Figure 1). A
12 weeks (post 
intervention) assessment
12 weeks assessment
24 weeks follow-up 
assessment




Baseline Assessment (N = 60)
0 weeks
Excluded
Not meeting inclusion criteria; refused 
to participate.
Allocated to 8 sessions of 
CBT-I (n=30)
Allocated to Control 
Condition (n=30)
Figure 1 Flow diagram for the BEST study.
Freeman et al. Trials 2013, 14:214 Page 3 of 7
http://www.trialsjournal.com/content/14/1/214psychological intervention control group is not included
in the design. We will instead examine how the treat-
ment works by including repeated measures of insomnia
and associated processes. Non-specific therapist factors
will also be assessed [17]. A two-group design makes the
successful completion of the trial much more feasible,
while the addition of a third group would not add value
in this instance. Randomization will be carried out inde-
pendently by an on-line system developed by the Oxford
Cognitive Health and Neuroscience Clinical Trials Unit.
The randomizer programme will balance the following
three variables: (i) sex (male, female), (ii) sleep problem
severity (low, 15 to 21 on the Insomnia Severity Index
(ISI); high, 22 to 28 on the ISI), and (iii) symptoms (hal-
lucination only, delusions only, hallucinations and delu-
sions). The trial therapist will inform patients of the
randomization outcome, so that the research worker
does not become unblinded. Rater assessments will be
blind. All patients will be informed of allocation by the
trial therapist to prevent the research assessors becom-
ing unblinded. Precautionary strategies will include en-
couraging the therapist to consider room use and diary
arrangements in the light of potential breaks of
masking and reminding patients by the assessor not to
talk about treatment allocation. Also, after the initial
assessment, the assessor will not look at the patient’s
clinical notes until the last of the ratings has been col-
lected. The success of the blinding will be monitored; ifthere are breaks in the blinding, another assessor will
be used from our research group. The reliability of the
rater on the key interviewer measures will be formally
assessed. The trial has received approval from the NHS
Research Ethics Committee South Central, Oxford C
(reference 12/SC/0138).
Participants
Patients will be recruited from services across the
Oxford Health NHS Foundation Trust, which covers a
population of 1.1 million. We will seek referrals from all
relevant outpatient and inpatient clinical teams who see
patients with schizophrenia and related diagnoses. The
inclusion criteria are: a current delusion or hallucination
that has persisted for at least three months; a score of
at least 2 on the distress scale of the Psychotic Symp-
tom Rating Scales (PSYRATS) for either a delusion or
hallucination [18]; a clinical diagnosis of schizophrenia,
schizoaffective disorder or delusional disorder (that is,
diagnosis of nonaffective psychosis (F2) in the Inter-
national Classification of Diseases and Diagnostic and
Statistical Manual IV); sleep difficulties lasting one
month or longer with an ISI score of 15 or above (that
is, above subthreshold insomnia). Participants must be
aged between 18 and 65, and, where changes in medi-
cation are being made, entry to the study would not
occur until at least a month after stabilization of dos-
age. It should be noted that we will be seeing patients
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generally been tried at length and symptoms are rela-
tively stable (persistent). It is increasingly recognized
that the action of neuroleptic medication occurs rapidly
[19,20]. Criteria for exclusion are: a primary diagnosis
of sleep apnoea, alcohol or substance dependency; an
organic syndrome or learning disability; a command of
spoken English inadequate for engaging in therapy; and
current individual CBT (though previous CBT experi-
ence is not an exclusion criterion). Written informed
consent will be obtained from all participants.
Planned interventions
The insomnia intervention will be provided in up to eight
sessions over 12 weeks. The 12-week window will allow
some flexibility for appointment times (it is quite common
for patients in this group to fail to attend appointments)
and the extension of intervals between the final two
sessions. The exact number of sessions will depend
on clinical appropriateness in the 12 week window. The
main techniques, which are standard sleep interventions
for CBT, are taken from four main sources [15,21-23].
The intervention is written in a manual, which we will
develop further. Initially, the sessions focus upon psycho-
education about sleep difficulties, assessment of the
triggering and maintenance of sleep difficulties, and goal-
setting. There is a checklist of factors likely to cause sleep
difficulties. Based on the assessment, the active therapeutic
techniques that are used included sleep hygiene, stimulus
control therapy (for example, setting appropriate and
regular sleep times, not doing anything else in the bed or
bedroom apart from sleeping, not staying in bed if not
able to sleep for longer than 20 to 30 minutes, stopping
daytime naps), relaxation, and, less often, cognitive tech-
niques to address unhelpful beliefs and attitudes about
sleep, attentional bias, monitoring, and safety behaviours.
The intervention is deliberately simplified, with the princi-
pal therapeutic technique being stimulus control; that is,
learning to associate bed with sleep. Participants are also
given written information as part of the intervention in
the form of leaflets to read between sessions and on
completion of the intervention. The intervention will
be carried out by a qualified clinical psychologist, who
carried out the case series therapy. Sessions will be
taped for assessment of adherence and for competence
[24]; when the purpose is clearly explained, we have
found that 80% of patients with psychosis agree to re-
cordings of sessions. We will obtain independent judge-
ments on the quality of therapy using a random
selection of therapy tapes. Patients will also be asked to
assess the therapist’s empathy [25]. Standard care is de-
livered according to national and local service protocols
and guidelines. Service use will be measured using the
Client Service Receipt Inventory [26].Outcome measures
Before entry into the trial, patients will be assessed
using the Duke Structured Interview Schedule for Sleep
Disorder Diagnoses (Edinger JD, Kirby AC, Lineberger
MD, Loiselle MM, Wohlgemuth WK, Means MK, un-
published). The key outcome measures will be levels of
insomnia as assessed by the ISI [27], and levels of delu-
sions and hallucinations as assessed by the PSYRATS
[18,28]. These measures were used in our case series
test. The ISI has been recommended by sleep experts
as a key outcome measure for trials [29], whereas the
PSYRATS is the best dimensional measure of psychotic
symptoms and has been used in large clinical trials
[30]. Both these key outcome measures have established
psychometric properties and our case series patients found
them easily understandable and helpful to assess relevant
experiences.
Secondary outcome assessments will include patient-
reported outcome measures: a psychometrically vali-
dated user-led assessment (CHOICE [31]) reflecting the
priorities, such as self-confidence, peace of mind and a
sense of being in control, of patients with psychosis; a
measure of quality of life, which includes a simple as-
sessment of subjective general health state (EQ-5D-5
levels [32]); and a self-reported measure of well-being
(the Warwick-Edinburgh Mental Well-being Scale [33]).
We will also include a self-reported measure of fatigue
(Multidimensional Fatigue Inventory [34]), a second
self-reported measure of sleep used in many insomnia
trials (the Pittsburgh Sleep Quality Index [35]), a self-
reported scale of suspicious thoughts (the Green et al.
Paranoid Thoughts Scale [36]), and a standard psychi-
atric interviewer-rated assessment (the Positive and
Negative Symptom Scale [37]). We will also ask partici-
pants to complete a brief sleep diary before each assess-
ment point, and take part in actigraph assessment (an
actigraph is a watch-like device that records movement
or activity and ambient light to produce an objective as-
sessment of sleep level); this will be an important oppor-
tunity to pilot these sleep assessments with this group.
We will also record service use, including medication
consumption (type, dose, and time taken), use of alcohol,
illicit drugs and nicotine, physical health history, adverse
events, and hospital admission data (including use of the
Client Service Receipt Inventory [26]). We will also, if
participants are willing, collect urine for 48 hrs before
each assessment, so that levels of melatonin can be
tested. For an exploratory examination of mediation we
will include: the Beck Anxiety Inventory [38], the Beck
Depression Inventory [39], a night-time worry scale and
an activity diary. To test for moderation, we will also
take a mouth swab to enable DNA analysis. We will also
carry out a qualitative evaluation of the patients’ experi-
ences and preferences concerning the CBT for insomnia
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tients using interpretative phenomenological analysis. A
semi-structured interview lasting 20–30 minutes will be
used, developed in consultation with our service user ad-
visors. Interviews will be tape recorded and then tran-
scribed before analysis.
Assessment and follow-up
The outcome measures will be completed before
randomization (0 weeks), at the end of therapy (12
weeks) and at a follow-up (24 weeks). Paper copies will
be kept of all assessments and data entered into an elec-
tronic database within one day of the assessment. All the
data entry for the two main outcomes will be double
checked. The baseline assessment must be completed
before randomization. The end of therapy assessment
must be carried out after therapy has been completed.
We will endeavour to have the repeat assessments car-
ried out at exactly the timings specified, but will allow a
two-week window for the post-therapy assessment and a
one-month window for the follow-up assessment. As
discussed, all assessments will be carried out blind to
group allocation, and if a break of blind does occur then
another assessor will be brought in to re-establish blind-
ness. Participants will be paid £15 for each assessment
session to compensate them for their time.
Assessment of safety
There were no adverse events in our initial case series
evaluation of CBT-I. The following will be considered as
adverse events: (i) all deaths; (ii) suicide attempts; (iii)
serious violent incidents; (iv) admissions to secure units;
and (v) formal complaints about therapy. We will also
scrutinize any instances of patients being admitted to
psychiatric hospital in the period of the therapy. These
adverse events are likely to come to the attention of the
assessor or therapist but we will also check medical
notes at the end of each participant’s time in the trial.
Responses to adverse events will be determined on a
case-by-case basis by the trial team.
Statistical analysis
All main analyses will be carried out at the end of the
last follow-up assessments (that is, there will be no
interim analyses) and will be based on the intention-to-
treat principle, with due consideration given to potential
biases arising from loss to follow-up. Parameter esti-
mates and confidence intervals of continuous outcomes
will be obtained using analysis of covariance, adjusting
for baseline variables. (We will also look at the effect of
treatment difference by controlling for initial overall
symptom severity (assessed by the Positive and Negative
Symptom Scale) and medication use as a sensitivity ana-
lysis). Absolute risk difference and relative risk will becalculated for binary outcomes. Rates of attrition and
loss to follow-up will be calculated for each time point.
We will also assess the correlations of each measure
across all time points. These findings will be used to in-
form the sample size for the definitive trial. For the
health economic analysis, quality adjusted life-years will
be used as an outcome measure, by combining EQ-5D
quality-of-life information with survival data. A cost-
utility analysis will be performed, in which the differ-
ences in mean costs between the CBT and standard care
groups will be divided by the difference in mean out-
comes between the two groups. The sample size of 60 is
based on our collective recruitment experience from
previous and current studies, and is considered adequate
for obtaining reasonably reliable sample size estimates
[40]. The patients will be recruited over 15 months. A
fully detailed statistical analysis plan will be written and
signed off by the investigator prior to any analysis by the
trial statistician.
Discussion
The importance of sleep in the occurrence of psychiatric
problems is becoming increasingly recognized [5,41]. The
BEST study will be the first randomized controlled test of
cognitive behaviour therapy for insomnia in patients with
nonaffective psychosis. The trial is funded for 24 months
and staff began in post in October 2012. Final outcome as-
sessments will be complete by the end of August 2014.
Therefore, the study results will become available in 2015.
We predict that the intervention will not only improve
sleep but lessen distressing positive symptoms of psych-
osis. Our experience is that the intervention is popular
since it focuses on a problem that the patient recognizes
and hence there is a clear shared outcome goal. In the
study we will be able to compare self-reported and more
objective markers of sleep (for example, actigraphy, mela-
tonin), while we will assess delusions and hallucinations
multidimensionally (for example, frequency, preoccupa-
tion, distress, and interference). If the study is successful,
we anticipate that the next step will be a definitive Phase
III clinical trial. We think it likely that in the future the
treatment of sleep problems will be an important tool in
the reduction, and perhaps prevention, of distressing
psychotic experiences.
Trial status
Patients began to enter the trial in December 2012. Re-
cruitment will continue for 15 months.
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